BIS Research Study Projects the Global FLT3 Inhibitors Market to Reach $2.06 Billion by 2032
FREMONT, Calif., Aug. 30, 2022 /PRNewswire/ -- The premium market intelligence study by BIS Research titled FLT3 Inhibitors Market - A Global and Regional Analysis projects the market to grow at a CAGR of 14.88%.
As per the study, the market was valued at $400.9 million in 2021 and is anticipated to reach $2.06 billion by 2032.
The scope of the report exclusively covered emerging and established pharmaceutical companies that are actively involved in developing and manufacturing different drug class therapies intended for the treatment of cancers with FLT3 positive mutations such as acute myeloid leukemia, renal cell carcinoma, and others.
In this report, monotherapies and combination therapies have been considered as a part of the study, such as Rydapt, Xospata, and Vanflyta. In addition, potential pipeline products are included in the study currently in their late development stage or have met their endpoints, such as Crenolanib, Dovitinib, and SKLB1028.
The global market covers major geographies, including North America, Europe, Asia-Pacific, and Rest-of-the-World.
The detailed study is a compilation of 17 market data tables and 105 figures spread through 152 pages and an in-depth TOC on "Global FLT3 Inhibitors Market – Analysis and Forecast, 2022-2032."
Demand - Drivers and Limitations
Following are the demand drivers for the FLT3 inhibitors market:
- Introduction of novel products
- Increasing incidence of acute myeloid leukemia
- Rising research and development investments
The market is expected to face some limitations as well due to the following challenges:
- High treatment costs impacting the adoption rate
- Disease relapse in FLT3 mutated AML
Analyst's Take on the Market:
According to Vaishali Chauhan, Research Analyst, BIS Research, "The global FLT3 inhibitors market is a small segment of the entire tyrosine kinase inhibitors market and is growing. Moreover, along with it, the rising interest of the pharmaceutical industry in developing and marketing novel drugs for treating blood cancers with FLT3 positive mutations is making headway in the growth of the global FLT3 inhibitors market. Until recently, patients suffering from FLT3 mutated AML were mainly treated with chemotherapy, which was not very efficient at improving survival rates. A new group of drugs known as FLT3 inhibitors is enhancing the outlook for people with the FLT3 positive mutation."
View the report on Global FLT3 Inhibitors Market
Existing Competitive Landscape
The companies that are profiled have been selected based on primary research inputs gathered from a network of industry experts and analyzing company coverage, product portfolio, and market penetration.
Some prominent names established in this market are:
- Cullinan Oncology, LLC
- Astellas Pharma Inc.
- Allarity Therapeutics, Inc.
- AROG Pharmaceuticals, Inc.
- Aptose Biosciences Inc.
- Novartis International AG
- Daiichi Sankyo Company, Limited
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- FUJIFILM Pharmaceuticals U.S.A., Inc.
- Jiangsu HengRui Medicine Co., Ltd.
Recent Developments in Global FLT3 Inhibitors Market
- In March 2021, Astellas Pharma's Xospata (Gilteritinib) met the overall survival endpoint in the COMMODORE trial of subjects having FLT3 mutated relapsed or refractory acute myeloid leukemia.
- In December 2021, Allarity Therapeutics submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for Dovitinib as a third-line treatment for renal cell carcinoma (RCC).
- In June 2021, Cullinan Oncology received investigational new drug (IND) clearance from the FDA for CLN-049 to treat relapsed/refractory AML.
Reasons to Buy this Report
This exclusive report on the FLT3 inhibitors market will help in the following ways:
- Aids in drug development
- Helps in targeting a segment for launching a new product
- Helps in understanding and comparing different commercialized products
- Aids in understanding the potential pipeline products
- Assists in exploring different indications
- Supports in analyzing the competitors' key developments
Who should buy this report?
Pharmaceutical and biopharmaceutical companies involved in drug development to treat FLT3 mutated AML should buy this report.
Request a Sample of this Report
BIS Research Related Market Studies:
Global Hematological Malignancies Emerging Therapeutics Market
About BIS Research:
BIS Research is a global B2B market intelligence and advisory firm focusing on deep technology and related emerging trends which can disrupt the market dynamics in the near future. We publish more than 200 market intelligence studies annually that focus on several deep technology verticals.
Our strategic market analysis emphasizes on market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.
BIS Research offers syndicate as well as custom studies and expert consultations to firms, providing them specific and actionable insights on novel technology markets, business models, and competitive landscape.
Contact:
Bhavya Banga
Email: [email protected]
BIS Research Inc.
39111 PASEO PADRE PKWY STE 313,
FREMONT CA 94538-1686
Visit our Blog @ https://bisresearch.com/news
Get Expert Insights @ https://community.insightmonk.com
Connect with us on LinkedIn @ https://www.linkedin.com/company/bis-research
Connect with us on Twitter@ https://twitter.com/BISResearch
Logo: https://mma.prnewswire.com/media/495163/BIS_Research_Logo.jpg
SOURCE BIS Research
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article